학술논문
Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer
Document Type
article
Author
Anniina Färkkilä; Doga C. Gulhan; Julia Casado; Connor A. Jacobson; Huy Nguyen; Bose Kochupurakkal; Zoltan Maliga; Clarence Yapp; Yu-An Chen; Denis Schapiro; Yinghui Zhou; Julie R. Graham; Bruce J. Dezube; Pamela Munster; Sandro Santagata; Elizabeth Garcia; Scott Rodig; Ana Lako; Dipanjan Chowdhury; Geoffrey I. Shapiro; Ursula A. Matulonis; Peter J. Park; Sampsa Hautaniemi; Peter K. Sorger; Elizabeth M. Swisher; Alan D. D’Andrea; Panagiotis A. Konstantinopoulos
Source
Nature Communications, Vol 11, Iss 1, Pp 1-13 (2020)
Subject
Language
English
ISSN
2041-1723
Abstract
A Phase I/II trial previously revealed variable anti-tumor efficacy of the PARP inhibitor niraparib in combination with the PD-1 inhibitor pembrolizumab in platinum-resistant ovarian cancer patients. Here, the authors perform an integrated genomic and immunomics analysis of tumor samples from the same patients and find potential predictive biomarkers of response to such combination therapy.